FDA Approves Amyvid for Alzheimer’s Diagnosis

News from the web:

Amyvid is a radiopharmaceutical developed by the Eli Lilly Company to aid in the diagnosis of Alzheimer’s disease by causing previously invisible beta amyloid plaque deposits in the brain to show up in PET scans. The FDA has recently approved Amyvid for clinical use although its use remains somewhat controversial.

Dr. Alois Alzheimer’s discovery of the physical changes in the brain in the early 1900s has caused researchers to focus on the plaque deposits he found in autopsied brains of diseased patients.  If the plaque causes the disease, discovering the plaque before a patient’s symptoms worsen could mean closing in on a cure.

Read all about it HERE

visit us at AlzheimerHeadlines.com